+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biogen Inc. - logo

Founded in 1978 Biogen Inc is a global biotechnology company with its headquarters in Cambridge, Massachusetts. In 2003 Biogen merged with Idec Pharmaceuticals to create Biogen Idec and acquired Syntonix Pharmaceuticals in 2007. In 2015 the company returned to its original name Biogen Inc and acquired Convergence Pharmaceuticals. Biogen focuses on drug discovery for a range of conditions including neuropathic pain, hemophilia, organ failure, neuromuscular disorders and oncology. Their product portfolio includes Rituxan, Avonex, Tecfidera and Eloctate.

Asia Pacific RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027 - Product Thumbnail Image

Asia Pacific RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • Report
  • January 2022
  • 84 Pages
  • Asia Pacific
From
Europe RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027 - Product Thumbnail Image

Europe RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • Report
  • January 2022
  • 83 Pages
  • Europe
From
LAMEA RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027 - Product Thumbnail Image

LAMEA RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • Report
  • January 2022
  • 84 Pages
  • Middle East, Africa
From
North America RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027 - Product Thumbnail Image

North America RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • Report
  • January 2022
  • 75 Pages
  • North America
From
Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence - Product Thumbnail Image

Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence

  • Report
  • February 2023
  • 22 Pages
  • Global
From
Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 91 Pages
  • Global
From
Migraine - Pipeline Review, H2 2020 - Product Thumbnail Image

Migraine - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 342 Pages
  • Global
From
Pharma M&A Deals 2023 - Top Themes - Thematic Research - Product Thumbnail Image

Pharma M&A Deals 2023 - Top Themes - Thematic Research

  • Report
  • January 2024
  • 25 Pages
  • Global
From
Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q3 2023 - Thematic Intelligence - Product Thumbnail Image

Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q3 2023 - Thematic Intelligence

  • Report
  • November 2023
  • 25 Pages
  • Global
From
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 555 Pages
  • Global
From
Traumatic Brain Injury - Pipeline Review, H2 2020 - Product Thumbnail Image

Traumatic Brain Injury - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 440 Pages
  • Global
From
Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029 - Product Thumbnail Image

Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029

  • Report
  • April 2021
  • 127 Pages
  • Global
From
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drugs in Development, 2021 - Product Thumbnail Image

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drugs in Development, 2021

  • Report
  • November 2021
  • 126 Pages
  • Global
From
Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update - Thematic Research - Product Thumbnail Image

Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update - Thematic Research

  • Report
  • June 2022
  • 16 Pages
  • Global
From
Neuroimmunology Drug Development - Thematic Research - Product Thumbnail Image

Neuroimmunology Drug Development - Thematic Research

  • Report
  • April 2022
  • 163 Pages
  • Global
From
CD40 Ligand - Pipeline Review, H2 2019 - Product Thumbnail Image

CD40 Ligand - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 74 Pages
  • Global
From
Drug Development Sector Scorecard - Q4 2021 Update - Thematic Research - Product Thumbnail Image

Drug Development Sector Scorecard - Q4 2021 Update - Thematic Research

  • Report
  • December 2021
  • 16 Pages
  • Global
From
Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028 - Product Thumbnail Image

Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028

  • Report
  • December 2019
  • 356 Pages
  • Global
From
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018 - Product Thumbnail Image

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 86 Pages
  • Global
From
Social Responsibility Trends in Healthcare - Thematic Intelligence - Product Thumbnail Image

Social Responsibility Trends in Healthcare - Thematic Intelligence

  • Report
  • March 2023
  • 54 Pages
  • Global
From
Loading Indicator